Cabotegravir pharmacokinetics in Asian population with and without HIV
{{output}}
Objective: Cabotegravir is approved for HIV treatment (with rilpivirine) and prevention. The established cabotegravir population pharmacokinetic (PPK) model included 1.2% Asian participants. We aimed to compare cabotegravir pharm... ...
